US FDA approves Rituxan/MabThera for the most common type of adult leukemia
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for people with either previously untreated (first-line) or previously treated (relapsed or refractory) CD20-positive chronic lymphocytic leukemia (CLL).
GSK rejects conclusions of Senate Committee on Finance Staff Report on Avandia
- Details
- Category: GlaxoSmithKline
The Staff Report of the Senate Committee on Finance draws conclusions on the safety of Avandia (rosiglitazone) that are based on analyses that are not consistent with the rigorous scientific evidence supporting the safety of the drug.
GSK rejects conclusions reported in The New York Times story on Avandia
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) rejects the conclusions about the safety of Avandia (rosiglitazone) reported in the February 20, 2010, New York Times story.
GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizantâ¢
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™(gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).
Genzyme Reports Financial Results for Fourth Quarter of 2009 and Full Year
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ), a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.
AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement
- Details
- Category: AstraZeneca
AstraZeneca and Rigel Pharmaceuticals today announced an exclusive worldwide license agreement for the global development and commercialisation of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications.
Abbott Completes Acquisition of Solvay Pharmaceuticals
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced that it has completed its EUR 4.5 billion ($6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary portfolio of pharmaceutical products and expanding Abbott's presence in key global emerging markets.
More Pharma News ...
- Abbott Receives U.S. FDA Approval for Heat-Stable Norvir® (ritonavir) Tablets
- Roche study drug may offer valuable new treatment option for patients with type 2 diabetes
- Lilly's Online, Interactive Health Education Program Receives Two Web Awards
- Novartis gains exclusive rights to Debio 025
- US FDA Approves New Indication for Crestor (Rosuvastatin Calcium)
- Denosumab Trial met Primary and all Secondary Endpoints
- Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness